Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 2.72 g/t Au over 139.9 metres at Golden Summit (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pasithea Therapeutics Equity Warrant Exp 11th Aug 2026 KTTAW

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small... see more

Recent & Breaking News (NDAQ:KTTAW)

Pasithea Therapeutics to Call Special Meeting of Stockholders

GlobeNewswire October 3, 2022

Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of Directors

GlobeNewswire September 20, 2022

Pasithea Therapeutics Further Strengthens its Scientific Advisory Board with the Appointment of Dr. Merit Cudkowicz

GlobeNewswire September 15, 2022

Pasithea Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 9, 2022

Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference

GlobeNewswire August 18, 2022

Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis

GlobeNewswire August 11, 2022

Pasithea Therapeutics Urges Stockholders to Reject Activist Camac Group's Unjustified Campaign

GlobeNewswire August 2, 2022

Pasithea Therapeutics Awarded a Drug Development Research Grant

GlobeNewswire July 14, 2022

Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond

GlobeNewswire June 23, 2022

Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC

GlobeNewswire June 22, 2022

Pasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022

GlobeNewswire April 14, 2022

Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022

GlobeNewswire March 30, 2022

Pasithea Therapeutics Announces Collaboration with The Glimpse Group

GlobeNewswire March 8, 2022

Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022

GlobeNewswire February 24, 2022

Pasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Daniel Weinberger

GlobeNewswire February 9, 2022

Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple Sclerosis

GlobeNewswire February 3, 2022

Pasithea Therapeutics Announces Opening of Mental Health Clinic in Los Angeles and Broadens Focus Beyond Ketamine Treatments

GlobeNewswire January 26, 2022

Pasithea Therapeutics Opens Second Ketamine Therapy Clinic in the United Kingdom

GlobeNewswire December 21, 2021

Pasithea Therapeutics Expands its Mobile Clinics into Florida and Nevada

GlobeNewswire December 1, 2021

Pasithea Therapeutics Corp. Announces Closing of $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules

GlobeNewswire November 29, 2021